ALT “En octobre 2020, nous avions annoncé que nous disposerions d’un encapsulateur BPF avant la fin 2022. Exactement deux ans plus tard, la machine est livrée. Je pense que cette machine témoigne de la remarquable capacité d’exécution de TreeFrog et Invetech. Mais plus important encore, elle constitue une échéance clé. Notre encapsulateur peut désormais être utilisé pour fabriquer des produits de thérapie cellulaire utilisables en clinique. Avec 3 autres machines BPF livrées en 2023, nous allons pouvoir accélérer nos programmes internes et ceux en partenariat en immuno-oncologie et médecine régénérative.”
Dr Frédéric Desdouits, Président, TreeFrog Therapeutics.
"Scaling-up iPSC-based cell therapies: towards clinical grade processes with biomimetic C-Stem technology"
Next Wednesday, don't miss Senior Application Scientist Odette Becheau oral presentation at the BELSACT Scientific Meeting in #Leuven.
Do not hesitate to connect with her!
After the largest, longest ph 3 of any CAR-T #celltherapy, @KitePharma's
Yescarta is the 1st treatment in nearly 30 yrs to show stat significant improvement in OS for initial treatment of relapsed/refractory large B-cell lymphoma versus historical SOC. europeanpharmaceuticalreview…
@treefrogtx' co-founder and CSO Maxime Feyeux will give a talk on scale-up at @JSRM_Official meeting (March 24).
Do not hesitate to connect with him on-site or during his 2-week trip through Tokyo, Kyoto, Kobe, Osaka and Fukuoka, from March 20th to April 1st.
#celltherapyforall
The @treefrogtx alginate encapsulation system efficiency could be due to its ability to recapitulate in capsulo a 3D lumenized colony that morphologically resembles an epiblast rosette, and which has higher cell viability than 2D colonies.
sciencedirect.com/science/ar…
Following our recent paper describing #hiPSC#ScaleUp in #10L#bioreactors, our CSO highlights how the C-Stem™ platform can impact the manufacturing of stem cell-derived therapies.
More videos answering frequently asked questions about C-Stem™ : treefrog.fr/stemcelljungle/
What does the C-Stem™ platform bring to the #CellTherapy field? For once I am the one answering questions in this short video about our latest paper in #Biomaterials. 5 other videos addressing FAQS about C-Stem are online: treefrog.fr/stemcelljungle/
Happening live TOMORROW! ⚠️ This is your last chance to sign for this webinar on #pluripotent stem cells with Dr. Maxime Feyeux (@FeyeuxMaxime): bit.ly/3YVjMiw
What can the human body 🧍 teach us about how to scale up high-quality #pluripotent stem cells (PSCs)?
Join us for a live webinar on March 7, with Dr. Maxime Feyeux (@FeyeuxMaxime), co-founder of TreeFrog Therapeutics (@treefrogtx), to find out. bit.ly/3YVjMiw
What can the human body 🧍 teach us about how to scale up high-quality #pluripotent stem cells (PSCs)?
Join us for a live webinar on March 7, with Dr. Maxime Feyeux (@FeyeuxMaxime), co-founder of TreeFrog Therapeutics (@treefrogtx), to find out. bit.ly/3YVjMiw
Releasing a #whitepaper on the lumenized rosette - the 3D conformation adopted by human #PluripotentStemCells in vivo !
Properties / PSC growth & quality / comparison with 2D/aggregates / Biomimetic PSC culture in large-scale bioreactors
Download : treefrog.fr/stemcelljungle/r…
TreeFrog dans le #FT120 !
Quelle trajectoire ? Quels jalons à venir ? Quel impact en France ?
2 min avec Jean-Luc TREILLOU, co-fondateur de @treefrogtx.
Bienvenue aux nouveaux entrants dans le FrenchTech120, et un grand merci à @LaFrenchTech !
What to find on our new scientific blog ?
#1 Exclusive & free resources: a list of #CellTherapy#trials based on #Pluripotent#StemCells, a white paper on the lumenized rosette – the specific 3D conformation adopted by hPSCs in vivo, interviews... treefrog.fr/stemcelljungle/
Press Release : Clinical-stage Japanese biotech Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors. Full press release: treefrog.fr/gaia-biomedicine…
@treefrogtx team will start 2023 in #SanFrancisco !
Frédéric Desdouits and Kévin Alessandri will attend the J.P. Morgan 41st annual Healthcare Meeting from January 9th to 12th 2023.
Feel free to reach out to schedule a meeting.
#JPMorgan#celltherapyforall
Meet us next week at iPSC-Derived Cell Therapies Summit, from December 6th to 7th in Boston !
Feel free to connect with our Boston team, CTO Kévin Alessandri and BD Officer Anthony Renodon, based in @LabCentral (@MassBio).
#Boston#celltherapyforall